Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 53.8%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 222,054 shares, an increase of 53.8% from the December 31st total of 144,352 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average daily trading volume, of 75,408 shares, the short-interest ratio is currently 2.9 days. Based on an average daily trading volume, of 75,408 shares, the short-interest ratio is currently 2.9 days. Approximately 3.9% of the shares of the company are short sold.

Armata Pharmaceuticals Trading Up 15.5%

Shares of NYSEAMERICAN:ARMP traded up $1.04 during trading on Monday, hitting $7.74. 45,643 shares of the company’s stock were exchanged, compared to its average volume of 57,773. The firm has a 50-day moving average price of $6.33 and a two-hundred day moving average price of $4.61. Armata Pharmaceuticals has a 1-year low of $0.90 and a 1-year high of $16.34. The firm has a market cap of $281.81 million, a P/E ratio of -4.78 and a beta of 1.42.

Institutional Investors Weigh In On Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its position in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 17.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,988 shares of the company’s stock after buying an additional 6,034 shares during the period. SeaCrest Wealth Management LLC owned about 0.11% of Armata Pharmaceuticals worth $274,000 as of its most recent SEC filing. 3.57% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Jones Trading started coverage on shares of Armata Pharmaceuticals in a report on Monday, January 5th. They issued a “buy” rating and a $15.00 price objective for the company. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $12.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.